FDA Panel Backs Amgen’s Nplate For Chronic Immune Thrombocytopenic Purpura
This article was originally published in The Pink Sheet Daily
Executive Summary
The platelet producer could have an important role in chronic ITP management, Oncologic Drugs Advisory Committee says.
You may also be interested in...
Amgen’s Nplate Approved With Restricted Access Program
FDA approval of the first platelet producer includes a REMS with a patient and physician tracking program.
Amgen’s Nplate Approved With Restricted Access Program
FDA approval of the first platelet producer includes a REMS with a patient and physician tracking program.
Nplate Risk Plan Includes Patient Support Initiatives
Prematurely issued press release announcing approval of Amgen chronic ITP therapy provides details on risk evaluation and mitigation strategies.